+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

DCGI grants emergency use permission to single-dose Sputnik Light Covid vaccine

Feb 6, 2022, 22:02 IST
PTI
New Delhi, Feb 6 (PTI) The Drugs Controller General of India has granted emergency use permission to single-dose Sputnik Light Covid vaccine in the country, Union Health Minister Mansukh Mandaviya said on Sunday.

This comes following recommendations of an expert panel of India's central drug authority to grant restricted emergency use authorisation to Sputnik Light subject to various regulatory provisions.

Advertisement

Sputnik-Light is the same as component-1 of Sputnik V.

"DCGI has granted emergency use permission to single-dose Sputnik Light COVID-19 vaccine in India. This is the ninth COVID-19 vaccine in the country. This will further strengthen the nation's collective fight against the pandemic," Mandaviya tweeted.

An official source said in light of recommendations of Subject Expert Committee (SEC) following a meeting on January 31, Dr Reddy's Laboratories presented its proposal for grant of permission to import Sputnik Light for restricted emergency use and booster dose vaccination along with analysis of safety and efficacy data including its benefit against Omicron.

The firm presented that Sputnik Light vaccine is approved in 29 countries, including Russia and Argentina.

Advertisement

"The SEC on COVID-19 of the CDSCO, which deliberated on the application by Dr Reddy's Laboratories, noted the safety and immunogenicity data presented by the firm from the Indian study is comparable with that of the ongoing Phase-3 clinical trial interim data from Russia," the source said.

The interim data of efficacy trial from Russia has shown 65.4 per cent efficacy, 21 days after immunization.

"After detailed deliberation, the SEC had recommended grant of permission for restricted use in emergency situation subject to various regulatory provisions including," the source said. PTI PLB NSD NSD

(This story has not been edited by www.businessinsider.in and is auto–generated from a syndicated feed we subscribe to.)
Next Article